The biotech industry breathed a collective sigh of relief with the news that on August 16 the US Court of Appeals for the Federal Court in New York upheld the Myriad patents on BRCA1 and BRCA2. The court came to the same 2–1 decision in 2011, but was asked to revisit the case by the Supreme Court, following its ruling on a related case. (In Mayo Collaborative Sciences v. Prometheus Labs, the Supreme Court found a certain diagnostic to represent a law of nature, and hence not be eligible for patent.) As before, the appeals court reversed two earlier district court findings—that Myriad's DNA test are products of nature, and that a method for screening potential cancer therapeutics employs basic scientific principles. Judge Kimberly Moore wrote that Congress has authorized an “expansive scope of patentable subject matter...and the USPTO [US Patent and Trademark Office] has allowed patents on isolated DNA sequences for decades,” saying it is a matter of policy, not for the courts to decide. Dan Vorhaus, editor of The Genomics Law Report, says “Those are the types of extra-legal policy-oriented questions that are at the heart of the Myriad litigation and will not be decided by litigation...[but] by policy makers.” he says.